Trial reportFrontiers in immunology2021
Trial report in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Bibliometric and visual analysis of gut microbiota research in functional bowel disorders from 2016 to 2025.Frontiers in medicine · 2026Pooled it
- The Health Benefits of Probiotic Lactiplantibacillus plantarum: A Systematic Review and Meta-Analysis.Probiotics and antimicrobial proteins · 2025Pooled it
- Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023.Digestion · 2024Guideline
- Lactiplantibacillus plantarum P9 for chronic diarrhea in young adults: a large double-blind, randomized, placebo-controlled trial.Nature communications · 2024Trial
- Trial
- Effect of Oral Intake ofNutrients · 2022Trial
- The gut microbiome axis: how Lactobacillus-fermented soymilk orchestrates health.Archives of microbiology · 2026Review
- Precision Microbiome Modulation: Exploring Lactobacillus spp. as A Targeted Strategy for Type 2 Diabetes Management.Current nutrition reports · 2026Review
- Isolation and Identification of a Canine-Derived Lactic Acid Bacterium with Probiotic Potential for Salmonellosis Prevention and Treatment.Probiotics and antimicrobial proteins · 2026Article
- Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.Journal of clinical medicine · 2026Review
- Genetically-Programmed Hypervesiculation of Lactiplantibacillus Plantarum Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Effects and Mechanisms of Lactiplantibacillus plantarum G83 on Enterotoxigenic Escherichia coli (ETEC)-Induced Intestinal Inflammation.Probiotics and antimicrobial proteins · 2026Article
- Functional Genomic Characteristics of Marine Sponge-AssociatedMicroorganisms · 2025Article
- Harnessing flavonoids to control probiotic function:Microbiology spectrum · 2025Article
- Article
- Strain-Specific Therapeutic Potential ofNutrients · 2025Article
- Effect of Lactiplantibacillus plantarum N-1 and isomaltose-oligosaccharide on promoting growth performance and modulating the gastrointestinal microbiota in newborn Hu sheep.Animal microbiome · 2025Article
- Lacidophilin tablets relieve irritable bowel syndrome in rats by regulating gut microbiota dysbiosis and intestinal inflammation.Scientific reports · 2025Article
- The role of gut microbiota in diarrhea and its alleviation through microbiota-targeted interventions.Frontiers in microbiology · 2025Review
- Harnessing the Power of Probiotics: Boosting Immunity and Safeguarding against Various Diseases and Infections.Recent advances in anti-infective drug discovery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome with diarrhea and functional diarrhea are both functional bowel disorders that cause chronic diarrhea. Chronic diarrhea is closely related to daily life and the psychological condition of diarrhea in patients, and probiotics can play a significant role in alleviating chronic diarrhea in some research. Lactobaccilus plantarum CCFM1143 can relieve diarrhea in mice caused by enterotoxigenic Escherichia coli (ETEC); however, its clinical effects remain unclear. This study aimed to assess the effects of CCFM1143 as a therapy for chronic diarrhea patients. Fifty-five patients with chronic diarrhea were randomly assigned into the probiotic group (n = 28) and the placebo group (n = 27), receiving the routine regimen with or without probiotics for 4 weeks, respectively. CCFM1143 can mitigate the apparent clinical symptoms and improve the health status and quality of life of patients. In addition, it could inhibit the increase in interleukin 6 (IL-6) and the decrease in motilin; modulate the short-chain fatty acids, especially acetic and propionic acids; and regulate the gut microbiota, particularly reducing the abundance of Bacteroides and Eggerthella and enriching the abundance of Akkermansia, Anaerostipes, and Terrisporobacter. In addition, treatment with probiotics showed clinical effectiveness in managing chronic diarrhea when compared with the placebo group. The findings could help to develop and further the application of probiotics for chronic diarrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.